Amniotics AB is a biopharmaceutical company dedicated to providing unique stem cell therapeutics to patients in need.
In the News
The biotech company Amniotics has developed technologies for extracting and refining amniotic fluid stem cells for cutting-edge therapy methods. In 2020, the company will enter the clinical phase, which may lead to a breakthrough in future cell therapies. https://www.di.se/brandstudio/amniotics/unika-stamceller-ur-fostervatten/
Researchers at the biotech company Amniotics in Lund has developed a lung specific stem cell for treatment of covid-19. The market for treating lung- and airway diseases is valued at 47 billion Euro. – At present, we are working day and night to finish our process...
Nio projekt för medicin och vaccin mot covid-19 pågår i Medicon Valley. Ett är Amniotics lungspecifika stamceller mot covid-19.
COVID19 – The Corona virus pandemic calls us to action
Amniotics AB is uniquely positioned to, and we believe it is our duty to, explore a novel treatment modality for severe respiratory issues related to infections from the corona virus SARS-CoV-2. Our research and development program over the last decade geared towards treatment of severe respiratory diseases has created the knowledge and experience that may be applied to treating respiratory issues associated with COVID19. The severity of the most affected patients calls us to action. We are answering that call.